Previous 10 | Next 10 |
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 1...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, August 8, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 20...
Aimmune Therapeutics ( AIMT -6.5% ) is down on below-average volume on the heels of a cautionary report on peanut allergy treatments by the non-profit Institute for Clinical and Economic Review (ICER). More news on: Aimmune Therapeutics, Inc., DBV Technologies S.A., Healthcare stocks...
Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community Aimmune Therapeutics (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening ...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for AR101, an investigational biologic ora...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the JMP Securities Life Sciences Conference on Wednesday...
Company to Share Updated Clinical Data on AR101 and Provide Perspective on Its Value to Society Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, will present at the Institute for Clinical and Economic ...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of its Executive Management Team will participate in a fireside chat at the Goldman Sachs 40 th Annual Healthcare Conference on...
News, Short Squeeze, Breakout and More Instantly...
Aimmune Therapeutics Inc. Company Name:
AIMT Stock Symbol:
NASDAQ Market:
Aimmune Therapeutics Inc. Website:
— Majority of Patients Experienced Low Rates of Adverse Events, Which Declined in Frequency and Severity with Continued Treatment — — Systemic Allergic Reactions and Epinephrine Use Were Low and Decreased Over Time — Aimmune Therapeutics, ...
-- Peanut Allergy is One of the Most Common Food Allergies in Europe -- -- Up to 1.6% of European Children Live with Potentially Life-Threatening Peanut Allergy -- Aimmune Therapeutics, Inc., a Nestlé Health Science Company, today announced that the European Com...
VEVEY, Switzerland , Sept. 14, 2020 /PRNewswire/ -- Société des Produits Nestlé S.A. ("Nestlé") announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. ("Purchaser"), is commencing today a cash tender offer to purchase all of the outstanding shares of common s...